[1]Kil BJ, Kim IW, Shin CY, et al. Comparison of IY81149 with omeprazole in rat reflux oesophagitis[J]. J Auton Pharmacol,2000, 20(5-6):291-296.
[2]Kwon D, Chae JB, Park CW, et al. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo[J]. Arzneimittelforschung, 2001, 51(3):204-213.
[3]Kim EJ, Lee RK, Lee SM, et al. General pharmacology of IY-81149, a new proton pump inhibitor[J]. Arzneimittelforschung, 2001, 51(1):51-59.
[4]周丽雅, 林三仁, 杨云生,等. 艾普拉唑对十二指肠溃疡患者胃内pH值的影响[J]. 中华内科杂志, 2010, 49(4):290-292.
[5]Wang H, Lang L, Ning O, et al. Pharmacokinetics, pharmacodynamics and safety of multiple-Infusion ilaprazole in healthy Chinese subjects[J]. Clin Drug Invest, 2016, 36(6):463-470.
[6]Ji XQ, Du JF, Chen G, et al. Efficacy of ilaprazole in the treatment of duodenal ulcers:a meta-analysis[J]. World J Gastroenterol, 2014, 20(17):5119-5123.
[7]李志坤, 王福文. 药物治疗应激性胃溃疡的研究进展[J]. 医学研究生学报, 2015,28(1):110-112.
[8]Wang L, Zhou L, Lin S, et al. A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial[J]. J Clin Gastroenterol, 2011, 45(4):322-329.
[9]Ho KY, Kuan A, Zao F, et al. Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers[J]. J Gastroenterol, 2009, 44(7):697-707.
[10]刘腾, 常艳璐, 韩容. 艾普拉唑的作用机制与临床评价[J]. 中国医院用药评价与分析, 2009, 9(10):724-725.
[11]Shin JS, Lee JY, Cho KH, et al. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study[J]. Aliment Pharmacol Ther, 2014, 40(5):548-561.
[12]艾普拉唑临床协作组. 艾普拉唑肠溶片治疗十二指肠溃疡的多中心、随机、双盲、阳性平行对照临床研究[J]. 中华消化杂志, 2009, 29(8):542-546.
[13]梁嘉碧, 冯文周, 边壮,等. 液相色谱-串联质谱法测定人血浆中艾普拉唑的浓度[J]. 药物分析杂志, 2013,33(6):935-940.
[14]吴骏, 陈集志, 徐小燕,等. 2011-2013年我院口服抗消化性溃疡药物的用药分析[J]. 东南国防医药, 2014,16(5):502-504.
[1]管晓音,孙文明,赵春花,等.超快速液相色谱法研究厄贝沙坦的药代动力学[J].医学研究与战创伤救治(原医学研究生学报),2010,12(02):102.
GUAN Xiao-yin,SUN Wen-ming,ZHAO Chun-hua,et al.Pharmacokinetic studies of irbesartan in beagle dog plasma by ultra-fast liquid chromatography[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2010,12(04):102.
[2]程俊霖,刘江慧,胡云芳,等.DPPⅣ抑制剂对2型糖尿病的Ⅰ期临床研究[J].医学研究与战创伤救治(原医学研究生学报),2014,16(06):592.[doi:10.3969/j.issn.1672-271X.2014.06.010]
CHENG Jun-lin,LIU Jiang-hui,HU Yun-fang,et al.Phase Ⅰ clinical study in a dipeptidyl peptidase Ⅳ inhibitor treatment of diabetes in type 2 diabetic patients[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2014,16(04):592.[doi:10.3969/j.issn.1672-271X.2014.06.010]
[3]朱婷婷,赵宇蕾,齐谢敏,等.1例大剂量甲氨蝶呤治疗骨肉瘤的药代动力学监护[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):119.[doi:10.3969/j.issn.1672-271X.2015.02.003]
ZHU Ting-ting,ZHAO Yu-lei,QI Xie-min,et al.Pharmacokinetic care of high-dose methotrexate in the treatment of osteosarcoma in 1 case[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(04):119.[doi:10.3969/j.issn.1672-271X.2015.02.003]